Abstract Library

#4116 A review of the Scottish national Peptide Receptor Radionuclide Therapy (PRRT) service with focus on patients with small bowel neuroendocrine tumors (SBNET) treated between April 2019 and March 2021

Introduction: Scottish National PRRT Service delivers 177Lu-Dotatate nationally at the Beatson West of Scotland Cancer Centre (BWoSCC). The NETTER-1 trial (Strosberg et al 2017) significantly changed the treatment and management of patients with gastroenteropancreatic NET (GEPNET). 177Lu-Dotatate demonstrated superiority in progression free survival (PFS) in patients with G1 and 2 midgut neuroendocrine tumors (NET). 177Lu-Dotatate 7.4 GBq 8 weekly gave 65% estimated progression free survival (PFS)at 20 months versus 10.8 % with 60mg octreotide intramuscularly 4 weekly (Strosberg et al 2017). Prior to this study everolimus was the most common 2nd line treatment for SBNET with a PFS of 14 months (Puscuddo et al 2017).

Conference:

Presenting Author:

Authors: Wotherspoon I, Charlick A, McIntosh D, Reed N,

Keywords: NETTER-1, Scottish PRRT Service,

#3334 Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)

Introduction: The NETTER-1 trial formed the basis for standard practice of PRRT, consisting of 4 cycles with follow-up imaging during midtreatment and after completion to evaluate disease response. However, in clinical practice the timing of midpoint imaging varies if performed at all, and it is unclear how often it influences subsequent management.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Norman A, Wee C, Hobday T, Kendi A, Johnson G,

Keywords: midpoint imaging, PRRT, clinical decision making,

#3245 A single institution experience with peptide receptor radionuclide therapy (PRRT) in non-midgut neuroendocrine tumors (NETs)

Introduction: The NETTER-1 trial showed that patients with midgut neuroendocrine tumors (NETs) had longer progression-free survival (PFS) when treated with peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in combination with octreotide LAR vs octreotide LAR alone.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Duan H

Authors: Duan H, Ferri V, Fisher G, Shaheen S, Davidzon G,

Keywords: non-midgut NET, NET, PRRT, 177Lu-Dotatate,

#2997 Benefits of 177Lu-DOTATATE in Patients with Advanced Neuroendocrine Tumours: Case Reports from Two Patients with High Disease Burden

Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wadsley J, Shah T,

Keywords: 177Lu-DOTATATE, metastases, quality of life,

#2698 Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ghaleb N

Authors: Ghaleb N, Dick R, Heraghty N, Zwane-Allen P, Vadrucci M,

Keywords: Nuclear Medicine, Hybrid Imaging, Relapse Therapy, PRRT, Survival, Toxicity,